Why Do Some Countries Allow What Others Ban?

Because medicines law is national, and classification is an administrative decision rather than a property of a molecule. No compound arrives in the world carrying a legal status. A status is conferred on it, by a particular authority, under a particular statute, at a particular date — and there are as many of those processes as there are countries running them.

That single fact accounts for almost all of the apparent contradiction people run into. A substance can be a prescription medicine in one country, an unlisted chemical in a second and a controlled substance in a third, simultaneously, with no error committed anywhere. The three authorities were not answering one question badly; they were each answering their own question under their own law.

What follows sets out the four places divergence actually enters: the starting definitions, the way those definitions are applied, the control schedules, and the limits of what harmonisation between countries can reach. It describes how the systems are built. It does not tell you the status of anything anywhere, and it is not legal advice.

Why isn't there a single global answer?

Because nobody has the authority to give one. Medicines regulation is an exercise of national sovereignty: each country legislates for its own territory, appoints its own regulator, maintains its own register of authorised products and its own control lists, and answers to its own courts.

International instruments do exist, and they matter, but their reach is narrower than people assume. Treaty frameworks oblige signatory states to control certain named substances and to cooperate on enforcement; they do not classify every compound, they do not create a global register, and they leave enormous amounts of the field untouched. Beneath the treaty floor, each country builds its own architecture.

The consequence is the thing that surprises people most: an authorisation is not portable. A marketing authorisation granted by one country's regulator has legal effect in that country's market, and confers no status whatever elsewhere until another authority has assessed the same product under its own law and entered it on its own register. Sponsors also file selectively, market by market, so a substance can be absent from a small country's register for purely commercial reasons that have nothing to do with any regulator's opinion of it.

So the absence of a single answer is not a gap waiting to be filled by better information. It is the structure of the field. Any source offering a global verdict on a compound's legal status is, at best, describing one country and generalising.

How can two countries read the same definition differently?

Because the definitions contain terms that require judgement, and the judgement is made case by case on particular evidence by particular officials. Even where the text is word-for-word identical across borders, the application of it is not.

Take the European definition, which is the most widely copied in the world. A medicinal product is caught on either of two limbs: presentation — being put forward as having properties for treating or preventing disease — or function, meaning administration with a view to restoring, correcting or modifying physiological functions by pharmacological, immunological or metabolic action 1. Both limbs are perfectly clear as sentences. Both require somebody to decide, on evidence, whether a particular product meets them.

The Court of Justice has been explicit about how much judgement that involves. In a case about whether a preparation fell inside the medicines code, it held that the function limb is not satisfied merely because a product contains a substance capable of physiological effect: the capacity must be scientifically established rather than merely possible, and the assessment must be made case by case, taking into account composition, pharmacological properties as they can be established in the current state of scientific knowledge, the manner of use, the extent of distribution and consumer familiarity 2.

Read that list of factors and the divergence becomes obvious rather than mysterious. "The current state of scientific knowledge" changes over time. "The extent of distribution" and "consumer familiarity" differ between markets by definition. Two authorities applying the identical test to the identical molecule, in different markets, at different dates, with different evidence in front of them, can reach different conclusions without either of them misreading the law.

Why don't control schedules line up?

Because scheduling is a separate administrative process from medicines authorisation, run by different bodies on different timetables, and because countries have chosen structurally different ways of covering compounds nobody has listed yet.

A schedule is a list, and lists are maintained by committees. Adding a substance typically requires a proposal, an evidence review, sometimes a public consultation, and a legislative or ministerial instrument. Each of those stages takes time, and the amount of time differs between administrations. At any given moment a compound may be listed in one country, under active review in a second and not yet considered in a third — a snapshot of three bureaucracies at three different points in the same process.

The supplementary mechanisms diverge more sharply still, and they are the real source of mismatch. The United States uses an analogue provision, under which a controlled substance analogue, to the extent intended for human consumption, is treated for the purposes of federal law as a substance in the most restrictive schedule 4 — a rule that makes status turn on a chemical's relationship to a listed substance rather than on its own appearance in a list. The United Kingdom took a quite different route, legislating a broad offence framework built around psychoactive effect, with schedules of exempted substances and exempted activities including research 5.

These are not variations on a theme. They are different architectures, and a compound's position relative to one of them tells you nothing reliable about its position relative to another. It is also why the fact that lists are actively maintained matters more than any particular list's contents on any particular day: the mechanisms exist because legislatures intend the space between named substances to keep shrinking.

Does a trade bloc solve it, and where does harmonisation stop?

It solves part of it, and stops well short of the rest. Harmonisation within a bloc mostly standardises the machinery of assessment and creates routes to mutual recognition — it does not replace national classification with a single continental verdict.

The European arrangement is the clearest working example. A centralised procedure exists under which certain classes of medicinal product — biotechnology-derived products, orphan medicines, and products containing new active substances for specified conditions — must be authorised through a single Union-level process, and an authorisation granted that way is valid throughout the Union 3. That is real harmonisation with real legal effect, and it removes an enormous amount of duplication.

The limits are equally real. The centralised route is mandatory only for defined categories; a great deal is still authorised nationally or through recognition procedures between member states. Common definitions are set by directive, which member states implement in their own legislation and their own authorities apply — which is exactly why a court had to rule on how the function limb should be applied at all 2. And whole neighbouring areas remain national: drug control scheduling, criminal law, licensing of premises and practitioners, and border enforcement priorities.

How can a supplier lawfully ship what a buyer cannot lawfully receive?

Because export law and import law are separate systems, binding different people, in different countries, under different tests. A dispatch that fully complies with the rules where it originates and a receipt that breaches the rules where it lands are entirely compatible facts about the same shipment.

The asymmetry is structural. A supplier is subject to the law of the place it operates in: what it may manufacture, how it must describe goods, what claims it may make, what it may export. A recipient is subject to the law of the place they are in: what may be imported, by whom, in what quantity, under what authorisation. Neither set of rules was drafted with the other in mind, and neither authority is obliged to check the other's.

Two further things follow that are worth stating flatly. A supplier's compliance is not a statement about a buyer's position, and it is not capable of being one — the supplier is not subject to the buyer's law and generally cannot know it. And a substance's absence from a control list somewhere else says nothing at all about its status where a reader actually is, because the classification that governs is the one made under the reader's own system 1.

This is the point on which the whole subject turns, so it is worth being unambiguous rather than diplomatic. The only law that governs your situation is the law of your own jurisdiction. Not the law where a supplier is based, not the law of the country whose regulator you happen to have read about, not the most permissive answer available anywhere. Your own.

And that is where this page stops, deliberately. What your jurisdiction's law says about a particular compound, in your particular circumstances, is answerable only from your national authority's own register and control lists, and only with a qualified professional in that jurisdiction to interpret them. A general description of why countries differ — which is all this is — cannot substitute for either, and nobody should treat it as though it could.